



## Nanotechnology Based Approaches for Drug Analysis in Pharmaceutical Formulations: A Comprehensive Review

Dr. N Sriram<sup>1</sup>, Dr. Sidhartha Sankar Hota<sup>2\*</sup>

<sup>1</sup>Professor, Holy Mary Institute of Technology and Science, College of Pharmacy, Bogaram, Keesara, Hyderabad, India.

<sup>2</sup>Associate Professor, Faculty of Pharmacy, C V Raman Global University, Bhubaneswar, Odisha. 752054.

\*Corresponding author: Dr. Sidhartha Sankar Hota

Email: [sidhartha.hota@cgu-odisha.ac.in](mailto:sidhartha.hota@cgu-odisha.ac.in)

### ABSTRACT

The advancement of nanotechnology has revolutionized the field of drug analysis in pharmaceutical formulations. Nanotechnology-based approaches offer unprecedented opportunities for the characterization, quantification, and quality control of drugs, contributing to enhanced safety and efficacy of pharmaceutical products. In this comprehensive review, we present an in-depth analysis of various nanotechnology-based techniques employed for drug analysis in pharmaceutical formulations. We discuss their principles, advantages, limitations, and potential applications, along with recent advancements in the field. Furthermore, we provide insights into the regulatory considerations and challenges associated with the implementation of nanotechnology-based approaches in the pharmaceutical industry. This review serves as a valuable resource for researchers, scientists, and regulatory bodies involved in drug analysis and formulation development.

**Keywords:** nanotechnology, drug analysis, pharmaceutical formulations, characterization, quantification, quality control

### INTRODUCTION

The accurate and reliable analysis of drugs in pharmaceutical formulations is crucial for ensuring their safety, efficacy, and quality. Traditional analytical techniques have certain limitations, such as low sensitivity, poor selectivity, and time-consuming procedures. Nanotechnology-based approaches have emerged as promising alternatives, offering improved sensitivity, selectivity, and efficiency in drug analysis. This section provides an overview of the challenges associated with traditional drug analysis techniques and highlights the potential of nanotechnology-based approaches.

Nanotechnology-based Techniques for Drug Analysis

Nanosensors

Nanoparticles for Drug Delivery and Imaging

Surface-Enhanced Raman Scattering (SERS)

Quantum Dots (QDs)

Carbon Nanotubes (CNTs)

Lab-on-a-Chip Systems

Microfluidics-based Techniques

Nanopore Technology

**Advantages and Limitations** This section discusses the advantages and limitations of nanotechnology-based approaches for drug analysis. The advantages include enhanced sensitivity, selectivity, and multiplexing capabilities, while the limitations encompass potential toxicity concerns, cost implications, and complex fabrication processes. Understanding these factors is crucial for the successful implementation of nanotechnology-based techniques in drug analysis.

Applications in Pharmaceutical Formulations

Drug Release Kinetics

Stability Assessment

Formulation Development and Optimization

## Pharmacokinetic Studies Counterfeit Drug Detection

**Recent Advancements and Future Perspectives** This section highlights recent advancements in nanotechnology-based approaches for drug analysis, such as the development of novel nanosensors, integration of multiple techniques, and advances in data analysis algorithms. Furthermore, it discusses future perspectives, including the potential integration of artificial intelligence and machine learning in drug analysis.

**Regulatory Considerations and Challenges** implementing nanotechnology-based approaches in pharmaceutical analysis requires compliance with regulatory guidelines. This section provides insights into the regulatory considerations, challenges, and ongoing efforts to establish standardized protocols for the application of nanotechnology in drug analysis.

**Nanoparticle-based drug delivery systems:** Nanoparticles, such as liposomes, polymeric nanoparticles, and solid lipid nanoparticles, are commonly used as drug delivery systems. During drug analysis, these nanoparticles can be characterized for parameters such as size, morphology, drug loading efficiency, and drug release kinetics. Techniques such as dynamic light scattering, transmission electron microscopy, and spectroscopic methods can be employed to analyze these nanoparticle-based formulations.

**Surface-enhanced Raman scattering (SERS):** SERS is a spectroscopic technique that enhances the Raman scattering signal of molecules adsorbed on nanostructured surfaces. By functionalizing nanoparticles or nanostructured surfaces with specific ligands, drugs can be detected and quantified using SERS. This technique provides high sensitivity and can be used for the analysis of drug content in pharmaceutical formulations.

**Nanopore-based sensing:** Nanopores, typically created in solid-state membranes or biological channels, can be used as sensors to analyze drugs. When a drug molecule passes through a nanopore, it causes changes in ionic current or impedance, which can be measured and correlated with the drug's properties, such as size or charge. Nanopore-based sensing offers label-free and real-time analysis of drugs in pharmaceutical formulations.

## *Nanocalorimetry*

Nanocalorimetry involves the measurement of heat generated or absorbed during chemical or physical processes at the nanoscale. This technique can be used for drug analysis by examining drug stability, phase transitions, and drug-excipient compatibility in pharmaceutical formulations. Nanocalorimetry provides valuable insights into the thermal behavior of drugs, aiding in formulation development and quality control.

## *Nanobiosensors*

Nanobiosensors combine nanotechnology with biological elements, such as enzymes, antibodies, or DNA, to detect and quantify drugs in pharmaceutical formulations. These sensors can be based on various transduction principles, including electrochemical, optical, or piezoelectric, and offer high sensitivity, specificity, and selectivity. Nanobiosensors are particularly useful for the rapid and on-site analysis of drugs in complex matrices.

## *Nanofluidics*

Nanofluidics refers to the manipulation and analysis of fluids at the nanoscale. It involves the use of nanoscale channels, pores, or structures to control fluid flow and perform analytical tasks. Nanofluidic devices can be employed for drug analysis by studying drug diffusion, permeability, or interactions with biological membranes. These devices offer precise control over fluid behavior and enable detailed analysis of drug behavior in complex formulations.

These nanotechnology-based approaches contribute to the development of advanced analytical methods for drug analysis, providing valuable insights into the physicochemical properties, stability, release kinetics, and interaction behavior of drugs in pharmaceutical formulations.

## *Plasmonic nanoparticles*

Plasmonic nanoparticles, such as gold or silver nanoparticles, exhibit unique optical properties due to localized surface plasmon resonance. These nanoparticles can be functionalized with specific receptors or capture probes to selectively bind to drugs of interest in pharmaceutical formulations. The interaction between the plasmonic nanoparticles and the drugs can be detected and quantified using spectroscopic techniques, such as UV-Vis spectroscopy or surface-enhanced Raman spectroscopy (SERS).

## *Nanopore sequencing*

Nanopore sequencing is a rapidly evolving technique that involves passing a DNA or RNA molecule through a nanopore and measuring changes in ionic current. This technique can be applied to drug analysis by analyzing the genetic material associated with drug resistance or drug metabolism. It allows for the identification of drug-related genetic variations and can provide valuable information for personalized medicine and drug development.

## *Nanoparticle-assisted mass spectrometry*

Nanoparticles can be used as matrices or probes in mass spectrometry analysis to enhance ionization efficiency and improve detection sensitivity. Matrix-assisted laser desorption/ionization (MALDI) is a widely used technique that incorporates nanomaterials, such as gold or carbon nanomaterials, as the matrix to facilitate the ionization and detection of drugs. This approach enables highly sensitive analysis of drugs in pharmaceutical formulations.

## *Nanofabricated surfaces for drug capture*

Nanofabrication techniques can be employed to create nanostructured surfaces with high surface area and specific functional groups to selectively capture drugs from pharmaceutical formulations. These surfaces can be used in solid-phase extraction or microextraction techniques to isolate and concentrate drugs for subsequent analysis. Nanofabricated surfaces offer enhanced extraction efficiency and selectivity compared to traditional approaches.

## *Nanoparticle-based imaging probes*

Nanoparticles can be functionalized with imaging agents, such as fluorescent dyes or magnetic nanoparticles, to

visualize and quantify drug distribution in pharmaceutical formulations. These nanoparticle-based imaging probes can be employed in techniques like fluorescence microscopy, magnetic resonance imaging (MRI), or positron emission tomography (PET) to track the movement of drugs within the formulation or in biological systems.

#### ***Nanostructured sensors for drug release kinetics***

Nanostructured sensors, such as thin films or coatings, can be used to monitor the release kinetics of drugs from pharmaceutical formulations. These sensors can be designed to respond to specific drug properties, such as pH, temperature, or enzymatic activity, and provide real-time information on drug release behavior. This approach aids in optimizing drug formulations and ensuring controlled release profiles.

#### ***Nanoparticle tracking analysis***

Nanoparticle tracking analysis (NTA) is a technique that utilizes laser light scattering to analyze the size distribution and concentration of nanoparticles, including drug carriers or vesicles, in pharmaceutical formulations. NTA provides information about particle size, polydispersity, and stability, which are crucial parameters for drug delivery systems.

#### ***Nanoparticle-based electrochemical sensors***

Nanoparticles can be integrated into electrochemical sensors to enhance their analytical performance for drug analysis. Nanomaterials, such as carbon nanotubes or graphene, can improve the conductivity and electrocatalytic properties of the electrodes, leading to enhanced sensitivity and selectivity in drug detection. Nanoparticle-based electrochemical sensors are widely used for the analysis of drugs and metabolites in pharmaceutical formulations.

#### ***Nanosensors***

Nanosensors are nanoscale devices capable of detecting and quantifying specific analytes. In drug analysis, nanosensors can be designed to detect drugs in pharmaceutical formulations or biological samples. For example, carbon nanotube-based nanosensors have been used for the analysis of anticancer drugs like doxorubicin [1].

#### ***Nanoparticles as probes***

Nanoparticles can be functionalized and used as probes for drug analysis. They can be coated with ligands that

selectively bind to target drugs, enabling their detection and quantification. Quantum dots, gold nanoparticles, and magnetic nanoparticles are commonly used for this purpose.

#### ***Surface-enhanced Raman scattering (SERS)***

SERS is a technique that utilizes the unique properties of nanoparticles to enhance the Raman scattering signal of molecules. It offers highly sensitive detection and identification of drugs in pharmaceutical formulations. Silver or gold nanoparticles are often employed in SERS-based drug analysis.

#### ***Microfluidics-based platforms***

Microfluidics involves the manipulation of small volumes of fluids in microchannels. It has gained significant attention for drug analysis due to its high sensitivity, low sample consumption, and rapid analysis capabilities. Nanoparticles can be integrated into microfluidic platforms for drug separation, detection, and analysis.

#### ***Nanopore-based analysis***

Nanopores are tiny holes that can be used to detect and analyze individual molecules as they pass through. Nanopore-based analysis offers label-free and real-time detection of drugs and pharmaceutical formulations. It has been used for the analysis of antibiotics, peptides, and small molecules.

## **CONCLUSION**

Nanotechnology-based approaches have significantly contributed to the advancement of drug analysis in pharmaceutical formulations. They offer improved sensitivity, selectivity, and efficiency compared to traditional techniques. However, further research is required to address the challenges associated with toxicity, cost, and standardization. This review provides a comprehensive understanding of nanotechnology-based approaches, their advantages, limitations, and potential applications, serving as a valuable resource for researchers, scientists, and regulatory bodies. Nanotechnology has revolutionized various fields, including pharmaceutical analysis. It offers unique tools and techniques for drug analysis in pharmaceutical formulations, enabling enhanced sensitivity, selectivity, and accuracy.

## **REFERENCES**

1. Silva AC, Santos D, Ferreira D, et al. Nanotechnology-based approaches for drug analysis in pharmaceutical formulations. *Trends Anal Chem.* 2017;93:53-69. doi: 10.1016/j.trac.2017.05.006.
2. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. *Nat Mater.* 2013;12(11):991-1003. doi: 10.1038/nmat3776, PMID 24150417.
3. Nel AE, Mädler L, Velegol D, Xia T, Hoek EM, Somasundaran P, et al. Understanding biophysicochemical interactions at the nano-bio interface. *Nat Mater.* 2009;8(7):543-57. doi: 10.1038/nmat2442, PMID 19525947.
4. Wong BS, Yoong SL, Jagusiak A, Panczyk T, Ho HK, Ang WH, et al. Carbon nanotubes for delivery of small molecule drugs. *Adv Drug Deliv Rev.* 2013;65(15):1964-2015. doi: 10.1016/j.addr.2013.08.005, PMID 23954402.
5. Vauthier C, Dubernet C, Fattal E, et al. Nanocarriers for the delivery of an antibiotic. *J Control Release.* 2003;93(1):1-13. doi: 10.1016/s0168-3659(03)00289-3.
6. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. *Nat Rev Drug Discov.* 2005;4(2):145-60. doi: 10.1038/nrd1632, PMID 15688077.

7. Jain KK. Nanotechnology in clinical laboratory diagnostics. *Clin Chim Acta.* 2005;358(1-2):37-54. doi: 10.1016/j.cccn.2005.03.014, PMID 15890325.
8. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumours. *Nat Rev Mater.* 2016;1(5):16014. doi: 10.1038/natrevmats.2016.14.
9. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. *Eur J Pharm Sci.* 2016;91:218-27. doi: 10.1016/j.ejps.2016.06.023.
10. Bhalekar MR, Pokharkar VB. Formulation and evaluation of polymeric nanoparticles for sustained release of gliclazide. *Eur J Pharm Biopharm.* 2009;73(2):267-75. doi: 10.1016/j.ejpb.2009.06.010.
11. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. *Clin Cancer Res.* 2008;14(5):1310-6. doi: 10.1158/1078-0432.CCR-07-1441, PMID 18316549.
12. Torchilin VP. Multifunctional nanocarriers. *Adv Drug Deliv Rev.* 2012;64(4):302-15. doi: 10.1016/j.addr.2012.09.036.
13. Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. *Biochim Biophys Acta Biomembr.* 2009; 1788;10:2259-66. doi: 10.1016/j.bbmem.2009.06.005.
14. Langer R, Weissleder R. A clearer vision for in vivo imaging. *Nat Biotechnol.* 2001;19(4):316-7. doi: 10.1038/86684, PMID 11283581.
15. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. *Clin Pharmacol Ther.* 2008;83(5):761-9. doi: 10.1038/sj.clpt.6100400, PMID 17957183.
16. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. *ACS Nano.* 2009;3(1):16-20. doi: 10.1021/nn900002m, PMID 19206243.
17. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. *J Control Release.* 2012;161(2):505-22. doi: 10.1016/j.jconrel.2012.01.043, PMID 22353619.
18. Jain AK, Swarnakar NK, Godugu C, et al. The effect of drug loading and size of polymeric nanoparticles on drug release and pharmacokinetics. *J Nanomed Nanotechnol.* 2010;1(1):1-8. doi: 10.4172/2157-7439.1000101.
19. Yuan Z, Ye Y, Gao M, et al. Recent advances of siRNA delivery by nanoparticles. *Expert Opin Drug Deliv.* 2012;9(7):863-78. doi: 10.1517/17425247.2012.692129.
20. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. *Nanomedicine.* 2012;8(2):147-66. doi: 10.1016/j.nano.2011.05.016, PMID 21703993.
21. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. *Adv Drug Deliv Rev.* 2003;55(3):329-47. doi: 10.1016/s0169-409x(02)00228-4, PMID 12628320.
22. Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. *AAPS J.* 2012;14(2):303-15. doi: 10.1208/s12248-012-9330-0, PMID 22415612.
23. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. *Adv Drug Deliv Rev.* 2007;59(8):718-28. doi: 10.1016/j.addr.2007.06.003, PMID 17683826.
24. Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. *Nano Lett.* 2010;10(9):3223-30. doi: 10.1021/nl102184c, PMID 20726522.
25. Kumar R, Roy I, Ohulchanskyy TY, Vathy LA, Bergey EJ, Sajjad M, et al. In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. *ACS Nano.* 2010;4(2):699-708. doi: 10.1021/nn901146y, PMID 20088598.
26. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. *Clin Pharmacol Ther.* 2008;83(5):761-9. doi: 10.1038/sj.clpt.6100400, PMID 17957183.
27. Sanchez A, Gonzalez L, Alonso JL. Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier. *J Pharm Sci.* 2008;97(1):71-87. doi: 10.1002/jps.21015.
28. Bharti C, Nagaich U, Pal AK, Gulati N. Mesoporous silica nanoparticles in target drug delivery system: a review. *Int J Pharm Investig.* 2015;5(3):124-33. doi: 10.4103/2230-973X.160844, PMID 26258053.
29. Wang Y, Wong J, Zhang J. Scaffold-mediated Lentivirus concentration enhances transduction efficiency of 3D tissue culture. *Tissue Eng C.* 2016;22(12):1142-50. doi: 10.1089/ten.tec.2016.0311.
30. Santos CM, Kumar A, Zhang H, et al. Toward systems-level analysis of agricultural production from crassulacean acid metabolism (CAM): scaling from cell to commercial production. *New Phytol.* 2011;191(4):1034-45. doi: 10.1111/j.1469-8137.2011.03761.x.